An interventional study of Walkasins in Sensory Peripheral Neuropathy, Balance; Distorted and Sensation Disorders, sponsored by RxFunction Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-12-22.
Sponsored by RxFunction Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Sensation Disorders with a site in United States — 8 open to participants now, 11 under way, 2 of them phase 3. Sensation Disorders · United States.
Among the 26 studies in Sensation Disorders with a site in United States, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2018, is one of 12 with no phase, and was the 8th registered.
87 studies on the registry are indexed under Sensation Disorders; 23 are open to participants now.
Browse Sensation Disorders studies →8 of the 26 studies in Sensation Disorders with a site in United States are open now. Recruiting first, the newest first:
Laboratoires Thea · Sites in United States, Australia, Belgium and 7 more countries
Ages 6+
Johns Hopkins University · Sites in United States
Ages 22–90
Johns Hopkins University · Sites in United States
Ages 65–90
Johns Hopkins University · Sites in United States
Ages 22–90
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Sensation Disorders studies recruiting now, 5 (33%) set no upper age limit and 6 (40%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 3 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 40 across 56 interventional studies indexed under Sensation Disorders.
Median enrollment 30 across the 19 interventional studies, 108 across the 6 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
RxFunction Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
RxFunction Inc. has 2 studies filed under Sensation Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Sensation Disorders with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT07256327Life UniversityChiropractic for Kids With Sensory Processing Challenges | 2026-12 |
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT05674786Johns Hopkins UniversityVestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction | 2026-12-31 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 26 studies in Sensation Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the long-term effects of Walkasins® use on clinical and subject-reported outcomes of balance and gait function, quality of life, physical activity/participation, pain, and medication use in persons with peripheral neuropathy who experience balance problems.
The main objectives of this single-arm study are to show a long-term (10 weeks), sustained improvement in Functional Gait Assessment (FGA) score >4 following Walkasins use as compared to participants' initial baseline assessments and to examine a potential relationship between initial baseline assessment data and long-term outcomes. The previous finding of a short-term FGA change >4 during Walkasins use (NCT02115633) justifies a pre-post study design to investigate the long-term effects of Walkasins use. Although the primary timeframe for the primary endpoint is 10 weeks, participants will return for follow-up visits at 26 weeks and 52 weeks of Walkasins use.
The investigators also intend to extend their observations of the short-term effects of Walkasins by replicating the randomized cross-over design of a previous short-term study. (The randomized cross-over replication will occur only during the baseline visit. The long-term study consists of a single arm.) This study may help to further refine the prescription criteria for Walkasins and determine whether or not the presence of a short-term response is indicative of long-term improvements.
A subset of 10 participants at the Harvard Medical School site will be enrolled in a pilot study to investigate possible structural and functional changes in cortical areas of the brain related to somatosensory connectivity using magnetic resonance imaging (MRI). Structural as well as functional MRI scans will be acquired at baseline and after 26 weeks of daily Walkasins use. An exploratory analysis of MRI data will be performed and related to functional clinical outcomes associated with Walkasins use over the same time period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off. After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits
Device: Walkasins
Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on. After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits.
Device: Walkasins
During the baseline visit, participants were randomized to two groups that applied to the first visit only. After the baseline visit, community-dwelling participants received Walkasins to wear over the next 52 weeks. They returned for follow-up visits at weeks 2, 6, 10, 26, and 52, during which they repeated the functional measures while wearing their Walkasins and responded to the questionnaires. Between weeks 10 and 26 and 26 and 52, they were contacted periodically to remind them of study requirements and to collect follow-up information regarding health changes, adverse events, pain scores, device usage, and device functioning. Note: Due to COVID-19 disruptions, some participants were not able to return for all in-person follow-up visits. They completed the patient-reported outcome measures via telephone visits.
Device: Walkasins
Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
Functional Gait Assessment
The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability. (Participants scoring 23 or higher on the baseline FGA were not included in this study because their peripheral neuropathy was not yet affecting their gait/balance significantly.)
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
10-Meter Walk Test
Gait speed (10-meter walk, timing the middle 6 meters) is assessed under two conditions: Participants are instructed (1) to walk at normal speed and (2) to walk as fast as they can. Higher numbers indicate faster speeds (i.e., more meters per second).
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Timed Up and Go Test (TUG)
The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Four-Stage Balance Test
The 4-Stage Balance Test is part of the Centers for Disease Control's recommended test protocol for balance function. It includes four gradually more challenging postures the subject is exposed to: (1) Stand with feet side by side. (2) Stand with feet in semi-tandem stance. (3) Stand with feet in tandem stance. (4) Stand on one leg. Participants pass each level if they can hold the stance for 10 seconds and then move on to the next stance. If they cannot hold the stance, the test ends. Higher times indicate better balance than lower times.
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Activities-specific Balance Confidence (ABC) Scale
Powell and Myers (1995) developed the Activities-specific Balance Confidence (ABC) Scale to detect levels of balance confidence in elderly persons. The ABC scale is a one-page questionnaire that asks questions about balance confidence when performing 16 different tasks. The items are rated on a scale of 0 to 100; a score of 0 indicates no confidence and a score of 100 indicates complete confidence when performing the task. The overall score is calculated by adding the individual items then dividing by the total number of items (16). The higher the score, the greater the person's balance confidence; thus, higher scores indicate that subjects are more confident of their balance.
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Vestibular Activities of Daily Living Scale (VADL)
The Vestibular Activities of Daily Living Scale (VADL) is a self-reported questionnaire that was developed to assess self-perceived disability in individuals with vestibular impairment. It evaluates the effects of vertigo and balance disorders on independence in 28 activities of daily living. Participants selected a number ranging from 1 = "Independent" to 10 = "Too Difficult, No Longer Perform." The scores on the 28 activities were averaged. The higher the score (up to 10), the greater is the person's self-perceived disability (i.e., the person feels less independence in activities of daily living). Lower averages of the 28 items indicate greater independence in activities of daily living (e.g., a healthy adult's VADL score most likely would be between 1.0 and 2.0).
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a nine-question tool for assessing depression and emotional well-being. Participants rate nine areas on a 0 to 3 scale in response to the question, "Over the last 2 weeks, how often have you been bothered by any of the following problems?" The rating scale is as follows: 0 = "Not at All," 1 = "Several Days," 2 = "More Than Half the Days," and 3 = "Nearly Every Day." A PHQ-9 total score of 0-4 points indicates "normal" or minimal depression. Scores between 5-9 points indicate mild depression; 10-14 points, moderate depression; 15-19 points, moderately severe depression; and 20 or more points, severe depression. (The minimum score on the PHQ-9 is 0; the maximum score is 27.) In short, lower scores indicate less depression.
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b
The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b measures the self-reported consequences of pain on relevant aspects of a person's life over the past 7 days and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). Higher scores (i.e., those greater than 50, the mean) indicate that the participants perceive their pain as interfering in their daily lives more than average; lower scores (i.e., those less than 50, the mean) indicate that the participants perceive their pain as interfering less than average in their daily lives, which would be considered a better outcome.
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
PROMIS Pain Intensity Form 1a
The PROMIS Pain Intensity Form 1a instrument asks participants to rate the intensity of their pain on average over the previous 7 days. It is universal rather than disease specific. The higher the score on a scale of 0 ("no pain") to 10 ("worst pain imaginable), the more intense is the person's perception of pain; lower scores indicate less intense perception of pain, a better outcome.
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
PROMIS Ability to Participate Short Form 8a
The PROMIS Ability to Participate in Social Roles and Activities assesses the participants' perceived ability to perform their usual social roles and activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., greater than 50, the mean) indicates participants perceive they have a better ability to participate in their roles and activities (i.e., a better outcome).
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
PROMIS Satisfaction With Participation in Social Roles Short Form 8a
The PROMIS Satisfaction with Social Roles and Activities items assess satisfaction with performing one's usual social roles and activities (e.g., "I am satisfied with my ability to participate in family activities"). PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., those greater than 50, the mean) indicates the respondents' greater satisfaction in regard to their ability to participate in their roles and activities (i.e., a better outcome).
Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Falls
Subjects were asked about the number of times they have fallen in the past 6 and 12 months and whether they incurred an injury from falling. (For this study, the researchers used the World Health Organization's definition of a fall: "an event which results in a person coming to rest inadvertently on the ground or floor or other lower level.") These data were compared to falls during their participation in the trial as tracked with a calendar and reported as adverse events. Falls data were monitored as overall number of falls and fallers pre-and post-study participation as well as the number of falls/1000 patient days. A lower number indicates fewer falls over 26 weeks (6 months).
Time frame: Baseline and 26 Weeks
Participants were recruited at five sites through various methods, including physician referral and recruitment posters. The first participant was enrolled on October 22, 2018, and the last participant was enrolled in April 2021.
| Milestone | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Started | 36 | 33 | 0 |
| Completed | 36 | 33 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Started | 0 | 0 | 69 |
| Completed | 0 | 0 | 36 |
| Not completed | 0 | 0 | 33 |
| Withdrew: Adverse event | 0 | 0 | 6 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 |
| Withdrew: Covid-19 disruptions at sites | 0 | 0 | 13 |
| Withdrew: Device dissatisfaction | 0 | 0 | 8 |
The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability. (Participants scoring 23 or higher on the baseline FGA were not included in this study because their peripheral neuropathy was not yet affecting their gait/balance significantly.)
| score on a scale | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 14.8 ± 4.1 | 14.8 ± 4.1 | 14.8 ± 4.1 |
| Baseline Crossover--Walkasins ON | 17.0 ± 4.5 | 18.2 ± 3.8 | — |
| Baseline Crossover--Walkasins OFF | 17.14 ± 4.5 | 16.3 ± 3.9 | — |
| Week 2 | — | — | 17.9 ± 4.7 |
| Week 6 | — | — | 18.2 ± 4.4 |
| Week 10 | — | — | 19.2 ± 5 |
| Week 26 | — | — | 19.1 ± 4 |
| Week 52 | — | — | 20.7 ± 5.3 |
Gait speed (10-meter walk, timing the middle 6 meters) is assessed under two conditions: Participants are instructed (1) to walk at normal speed and (2) to walk as fast as they can. Higher numbers indicate faster speeds (i.e., more meters per second).
| Meters/Second | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline Normal Gait Speed | 0.90 ± 0.29 | 0.85 ± 0.19 | 0.88 ± 0.25 |
| Baseline Crossover--Walkasins ON | 0.92 ± 0.28 | 0.91 ± 0.19 | — |
| Baseline Crossover--Walkasins OFF | 0.95 ± 0.29 | 0.90 ± 0.17 | — |
| Week 2 Normal Gait Speed | — | — | 0.94 ± 0.28 |
| Week 6 Normal Gait Speed | — | — | 0.95 ± 0.27 |
| Week 10 Normal Gait Speed | — | — | 0.97 ± 0.26 |
| Week 26 Normal Gait Speed | — | — | 0.97 ± 0.28 |
| Week 52 Normal Gait Speed | — | — | 1.02 ± 0.30 |
The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.
| Seconds | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 13.9 ± 6.2 | 13.5 ± 4.5 | 13.7 ± 5.5 |
| Baseline Crossover--Walkasins ON | 13.7 ± 5.2 | 12.8 ± 3.9 | — |
| Baseline Crossover--Walkasins OFF | 13.2 ± 5.8 | 12.7 ± 3.7 | — |
| Week 2 | — | — | 12.8 ± 4.2 |
| Week 6 | — | — | 12.4 ± 4.2 |
| Week 10 | — | — | 12.1 ± 3.6 |
| Week 26 | — | — | 12.3 ± 3.4 |
| Week 52 | — | — | 12.2 ± 3.7 |
The 4-Stage Balance Test is part of the Centers for Disease Control's recommended test protocol for balance function. It includes four gradually more challenging postures the subject is exposed to: (1) Stand with feet side by side. (2) Stand with feet in semi-tandem stance. (3) Stand with feet in tandem stance. (4) Stand on one leg. Participants pass each level if they can hold the stance for 10 seconds and then move on to the next stance. If they cannot hold the stance, the test ends. Higher times indicate better balance than lower times.
| Seconds | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 24.2 ± 6.9 | 26.5 ± 8.0 | 25.3 ± 7.5 |
| Baseline Crossover--Walkasins ON | 25.4 ± 7.5 | 26.6 ± 6.4 | — |
| Baseline Crossover--Walkasins OFF | 26.0 ± 6.9 | 27.7 ± 6.6 | — |
| Week 2 | — | — | 27.1 ± 8.0 |
| Week 6 | — | — | 27.4 ± 7.4 |
| Week 10 | — | — | 27.3 ± 6.9 |
| Week 26 | — | — | 28.4 ± 5.6 |
| Week 52 | — | — | 31.1 ± 6.8 |
Powell and Myers (1995) developed the Activities-specific Balance Confidence (ABC) Scale to detect levels of balance confidence in elderly persons. The ABC scale is a one-page questionnaire that asks questions about balance confidence when performing 16 different tasks. The items are rated on a scale of 0 to 100; a score of 0 indicates no confidence and a score of 100 indicates complete confidence when performing the task. The overall score is calculated by adding the individual items then dividing by the total number of items (16). The higher the score, the greater the person's balance confidence; thus, higher scores indicate that subjects are more confident of their balance.
| score on a scale | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline Crossover | 58.2 ± 17.3 | 61.2 ± 16.2 | 59.6 ± 16.7 |
| Week 2 | — | — | 62.5 ± 15.2 |
| Week 6 | — | — | 62.3 ± 16.9 |
| Week 10 | — | — | 63.6 ± 14.8 |
| Week 26 | — | — | 62.1 ± 16.5 |
| Week 52 | — | — | 65.2 ± 16.7 |
The Vestibular Activities of Daily Living Scale (VADL) is a self-reported questionnaire that was developed to assess self-perceived disability in individuals with vestibular impairment. It evaluates the effects of vertigo and balance disorders on independence in 28 activities of daily living. Participants selected a number ranging from 1 = "Independent" to 10 = "Too Difficult, No Longer Perform." The scores on the 28 activities were averaged. The higher the score (up to 10), the greater is the person's self-perceived disability (i.e., the person feels less independence in activities of daily living). Lower averages of the 28 items indicate greater independence in activities of daily living (e.g., a healthy adult's VADL score most likely would be between 1.0 and 2.0).
| score on a scale | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 3.97 ± 1.13 | 3.82 ± 1.15 | 3.89 ± 1.14 |
| Week 2 | — | — | 3.49 ± 1.1 |
| Week 6 | — | — | 3.66 ± 1.09 |
| Week 10 | — | — | 3.78 ± 1.03 |
| Week 26 | — | — | 3.66 ± 1.22 |
| Week 52 | — | — | 3.62 ± 1.12 |
The PHQ-9 is a nine-question tool for assessing depression and emotional well-being. Participants rate nine areas on a 0 to 3 scale in response to the question, "Over the last 2 weeks, how often have you been bothered by any of the following problems?" The rating scale is as follows: 0 = "Not at All," 1 = "Several Days," 2 = "More Than Half the Days," and 3 = "Nearly Every Day." A PHQ-9 total score of 0-4 points indicates "normal" or minimal depression. Scores between 5-9 points indicate mild depression; 10-14 points, moderate depression; 15-19 points, moderately severe depression; and 20 or more points, severe depression. (The minimum score on the PHQ-9 is 0; the maximum score is 27.) In short, lower scores indicate less depression.
| score on a scale | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 5.19 ± 4.63 | 4.30 ± 3.53 | 4.77 ± 4.13 |
| Week 2 | — | — | 3.97 ± 3.96 |
| Week 6 | — | — | 4.12 ± 4.16 |
| Week 10 | — | — | 4.18 ± 4.62 |
| Week 26 | — | — | 4.19 ± 4.03 |
| Week 52 | — | — | 4.83 ± 4.95 |
The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b measures the self-reported consequences of pain on relevant aspects of a person's life over the past 7 days and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). Higher scores (i.e., those greater than 50, the mean) indicate that the participants perceive their pain as interfering in their daily lives more than average; lower scores (i.e., those less than 50, the mean) indicate that the participants perceive their pain as interfering less than average in their daily lives, which would be considered a better outcome.
| T-score | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 52.6 ± 8.3 | 50.1 ± 8.7 | 51.4 ± 8.5 |
| Week 2 | — | — | 51.7 ± 7.8 |
| Week 6 | — | — | 51.1 ± 8.9 |
| Week 10 | — | — | 52.2 ± 8.5 |
| Week 26 | — | — | 51.2 ± 8.5 |
| Week 52 | — | — | 52.8 ± 9.1 |
The PROMIS Pain Intensity Form 1a instrument asks participants to rate the intensity of their pain on average over the previous 7 days. It is universal rather than disease specific. The higher the score on a scale of 0 ("no pain") to 10 ("worst pain imaginable), the more intense is the person's perception of pain; lower scores indicate less intense perception of pain, a better outcome.
| score on a scale | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 3.2 ± 2.6 | 2.4 ± 2.0 | 2.8 ± 2.3 |
| Week 2 | — | — | 2.6 ± 2.1 |
| Week 6 | — | — | 2.8 ± 2.5 |
| Week 10 | — | — | 2.7 ± 2.4 |
| Week 26 | — | — | 2.7 ± 2.1 |
| Week 52 | — | — | 3.2 ± 2.9 |
The PROMIS Ability to Participate in Social Roles and Activities assesses the participants' perceived ability to perform their usual social roles and activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., greater than 50, the mean) indicates participants perceive they have a better ability to participate in their roles and activities (i.e., a better outcome).
| score on a scale | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 48.8 ± 7.7 | 50.7 ± 8.7 | 49.7 ± 8.2 |
| Week 2 | — | — | 51.1 ± 7.5 |
| Week 6 | — | — | 50.9 ± 7.3 |
| Week 10 | — | — | 51.1 ± 7.9 |
| Week 26 | — | — | 52.0 ± 8.1 |
| Week 52 | — | — | 48.7 ± 7.9 |
The PROMIS Satisfaction with Social Roles and Activities items assess satisfaction with performing one's usual social roles and activities (e.g., "I am satisfied with my ability to participate in family activities"). PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., those greater than 50, the mean) indicates the respondents' greater satisfaction in regard to their ability to participate in their roles and activities (i.e., a better outcome).
| score on a scale | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Baseline | 47.7 ± 6.3 | 49.9 ± 8.1 | 48.7 ± 7.3 |
| Week 2 | — | — | 49.2 ± 7.5 |
| Week 6 | — | — | 50.1 ± 7.9 |
| Week 10 | — | — | 50.4 ± 8.4 |
| Week 26 | — | — | 51.0 ± 8.3 |
| Week 52 | — | — | 49.4 ± 8.5 |
Subjects were asked about the number of times they have fallen in the past 6 and 12 months and whether they incurred an injury from falling. (For this study, the researchers used the World Health Organization's definition of a fall: "an event which results in a person coming to rest inadvertently on the ground or floor or other lower level.") These data were compared to falls during their participation in the trial as tracked with a calendar and reported as adverse events. Falls data were monitored as overall number of falls and fallers pre-and post-study participation as well as the number of falls/1000 patient days. A lower number indicates fewer falls over 26 weeks (6 months).
| Number of Participant Falls | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Pre-Study/Baseline | — | — | 53 |
| Week 26 | — | — | 39 |
Collected over Adverse events were collected during the period of each subject's participation, a maximum of 52 weeks per participant. (The average duration of subjects' participation in the study was 271 days.). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baseline Cross-over Group A--Walkasins ON Then OFF | — | — | — |
| Baseline Cross-over Group B--Walkasins OFF Then ON | — | — | — |
| Single-Arm Long-Term Follow-up (Walkasins ON) | 1/69 (1.4%) | 10/69 (14.5%) | 24/69 (34.8%) |
| Event | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| HospitalizationsCardiac disorders | — | — | 2/69 |
| HospitalizationsRespiratory, thoracic and mediastinal disorders | — | — | 2/69 |
| HospitalizationsInjury, poisoning and procedural complications | — | — | 2/69 |
| HospitalizationBlood and lymphatic system disorders | — | — | 1/69 |
| HospitalizationCardiac disorders | — | — | 1/69 |
| HospitalizationBlood and lymphatic system disorders | — | — | 1/69 |
| HospitalizationPsychiatric disorders | — | — | 1/69 |
| HospitalizationSurgical and medical procedures | — | — | 1/69 |
| Event | Baseline Cross-over Group A--Walkasins ON Then OFF | Baseline Cross-over Group B--Walkasins OFF Then ON | Single-Arm Long-Term Follow-up (Walkasins ON) |
|---|---|---|---|
| Falls with Minor InjuriesGeneral disorders | — | — | 24/69 |
| Skin IrritationSkin and subcutaneous tissue disorders | — | — | 9/69 |
| Knee PainMusculoskeletal and connective tissue disorders | — | — | 5/69 |
| Hip PainMusculoskeletal and connective tissue disorders | — | — | 4/69 |
| Age, Categorical(Participants) | Single-Arm Long-Term Use |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 62 |
| Sex: Female, Male(Participants) | Single-Arm Long-Term Use |
|---|---|
| Female | 17 |
| Male | 52 |
| Ethnicity (NIH/OMB)(Participants) | Single-Arm Long-Term Use |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 65 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Single-Arm Long-Term Use |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 66 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Single-Arm Long-Term Use |
|---|---|
| United States | 69 |
| Weight (kg)(Kilograms) | Single-Arm Long-Term Use |
|---|---|
| Mean | 89.7 ± 18.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Dec 2021, 38 months.
Results were first posted in Dec 2022, 11 months after primary completion.
Of 32 interventional studies with no phase under Sensation Disorders, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 45. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RxFunction Inc.